Prostatype Genomics ABOSTO:PROGEN -8.33%25 PS Ratio is 15.00 as of Jul. 05, 2026, which is 98% below its 10-year median of 758.09. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 89.05% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prostatype Genomics AB's share price is kr0.33.
Prostatype Genomics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.02. Hence, Prostatype Genomics AB's PS Ratio for today is 15.00.
Good Sign:
Prostatype Genomics AB stock PS Ratio (=18.33) is close to 2-year low of 18.33.
The historical rank and industry rank for Prostatype Genomics AB's PS Ratio or its related term are showing as below:
OSTO:PROGEN'
s PS Ratio Range Over the Past 10 Years
Min: 1.25 Med: 758.09 Max: 14393.97
Current: 15
During the past 7 years, Prostatype Genomics AB's highest PS Ratio was 14393.97. The lowest was 1.25. And the median was 758.09.
OSTO:PROGEN's PS Ratio is ranked worse than 89.05% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.86
vs OSTO:PROGEN: 15.00
Prostatype Genomics AB revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -87.60% per year.
During the past 7 years, Prostatype Genomics AB's highest 3-Year average Revenue per Share Growth Rate was 115.10% per year. The lowest was -87.60% per year. And the median was -72.50% per year.
Back to Basics: PS Ratio
Prostatype Genomics AB (OSTO:PROGEN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: PS Ratio Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Prostatype Genomics AB's Share Price of today is kr0.33.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Prostatype Genomics AB (OSTO:PROGEN) has a PS Ratio of 15.00 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prostatype Genomics AB and its competitors. This is 98% below median its historical median of 758.09. Over the past decade, Prostatype Genomics AB's PS Ratio has ranged from 1.25 to 14,393.97. According to the industry distribution chart, Prostatype Genomics AB ranks #179 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 89.1%.
Is Prostatype Genomics AB's PS Ratio too high?
Prostatype Genomics AB's current PS Ratio of 15.00 is 98% below median its 10-year median of 758.09. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 14,393.97. The Medical Diagnostics & Research industry median PS Ratio is 2.86. Prostatype Genomics AB's value of 15.00 is 424.5% above this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #179 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #179 out of 201 companies for PS Ratio. This places Prostatype Genomics AB in the lower half of its industry. The industry median PS Ratio is 2.86. Prostatype Genomics AB's value of 15.00 is 424.5% above this benchmark. Historically, Prostatype Genomics AB's own PS Ratio has ranged from 1.25 to 14,393.97 over the past decade. While the company's 10-year median is 758.09 vs. the industry median of 2.86, Prostatype Genomics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.86, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current PS Ratio of 15.00 is 424.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current PS Ratio is 15.00, which is 98% below median its own 10-year median of 758.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.33 — trading 200% above its estimated fair value. The current PS Ratio is 15.00, which is 98% below median its 10-year median of 758.09 and 424.5% above the Medical Diagnostics & Research industry median of 2.86. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current PS Ratio is 15.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.33 is trading 200% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
PS Ratio: 15.00 (98% below median its 10-year median of 758.09)
GF Value™: kr0.11 vs. price of kr0.33 (200% above fair value)
Industry Position: 424.5% above the Medical Diagnostics & Research median (#179 of 201)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
